Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. OPRX
OPRX logo

OPRX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
6.855
Open
6.560
VWAP
6.68
Vol
401.45K
Mkt Cap
125.13M
Low
6.505
Amount
2.68M
EV/EBITDA(TTM)
7.67
Total Shares
18.76M
EV
125.75M
EV/OCF(TTM)
6.72
P/S(TTM)
1.15
OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.
Show More

Events Timeline

(ET)
2026-03-06
09:40:00
OptimizeRx Trading Halted Due to Volatility
select
2026-03-05 (ET)
2026-03-05
16:10:00
OptimizeRx Reports Q4 Revenue of $32.24M
select
2026-03-05
16:10:00
Company Sees FY26 Adjusted EBITDA of $21M-$25M
select
2026-03-05
16:10:00
OptimizeRx Authorizes Share Repurchase Program Up to $10M
select

News

Benzinga
9.5
03-06Benzinga
OptimizeRx Shares Decline Amid Market Uncertainty
  • Earnings Beat Expectations: OptimizeRx recently reported Q4 earnings of 51 cents per share, surpassing the consensus estimate of 23 cents, with revenues reaching $32.2 million compared to the expected $31.1 million, and adjusted EBITDA of $12.0 million, indicating a strong financial performance.
  • 2026 Forecast Downgrade: The company updated its fiscal year 2026 guidance, projecting revenues between $109 million and $114 million, down from the previous forecast of $118 million to $124 million, while adjusted EBITDA is expected to fall between $21 million and $25 million, potentially creating near-term headwinds for the business.
  • Increased Market Volatility: OptimizeRx shares fell 17.53% to $6.21 on Friday, trading 19.7% below its 20-day simple moving average and 50.1% below its 100-day SMA, indicating a bearish trend, with the stock positioned closer to its 52-week lows, suggesting a struggle for upward momentum.
  • Analyst Rating Changes: Despite an average price target of $23.08 and a Buy rating, analysts from Stifel and Stephens & Co. have lowered their targets to $17.00, reflecting a cautious outlook on the company's future performance, which may impact investor confidence.
seekingalpha
9.5
03-06seekingalpha
OptimizeRx Exceeds Q4 2025 Expectations with Strong Financial Results
  • Strong Financial Performance: OptimizeRx reported Q4 2025 revenue of $32.2 million and adjusted EBITDA of $12 million, exceeding market expectations and demonstrating successful adjustments in product mix and channel strategies.
  • Gross Margin Improvement: The gross margin for Q4 2025 reached 74.8%, up from 68.1% in Q4 2024, reflecting optimization in solution and channel partner mix, which enhances profitability.
  • Conservative 2026 Outlook: Management projects 2026 revenue between $109 million and $114 million, with adjusted EBITDA of $21 million to $25 million, indicating a cautious stance due to market uncertainties and client spending patterns.
  • Share Repurchase Program: The Board authorized a $10 million share repurchase program to be financed through available cash and cash equivalents, aimed at enhancing shareholder value and addressing market volatility.
seekingalpha
9.5
03-05seekingalpha
OptimizeRx Reports Q4 2025 Earnings Beat with Strong EBITDA Growth
  • Earnings Beat: OptimizeRx reported a Q4 2025 non-GAAP EPS of $0.51, surpassing expectations by $0.29, which highlights a significant improvement in profitability and boosts investor confidence.
  • Slight Revenue Decline: The company generated $32.2 million in revenue for Q4 2025, a 0.3% year-over-year decrease, yet it exceeded market expectations by $1.29 million, indicating relative revenue stability in a competitive market.
  • Significant EBITDA Growth: Adjusted EBITDA for Q4 2025 rose to $12.0 million, up 36.4% from $8.8 million in the same quarter of 2024, reflecting successful cost control and operational efficiency improvements.
  • Annual Gross Profit Increase: For the full year 2025, gross profit reached $73.6 million, a 24.5% increase from $59.4 million in 2024, demonstrating ongoing improvements in profitability and market share.
seekingalpha
9.5
03-04seekingalpha
OptimizeRx Set to Announce Q4 Earnings on March 5
  • Earnings Announcement: OptimizeRx is scheduled to release its Q4 earnings report on March 5, after market close, drawing significant attention from investors regarding its performance.
  • Declining EPS Expectations: The consensus EPS estimate stands at $0.22, reflecting a 26.7% year-over-year decline, indicating potential profitability challenges for the company.
  • Revenue Forecast Drop: The anticipated revenue for Q4 is $30.91 million, down 4.3% year-over-year, highlighting weakened market demand and increased competition.
  • Historical Performance Metrics: Over the past two years, OptimizeRx has exceeded EPS estimates 88% of the time and revenue estimates 75% of the time, demonstrating a degree of effectiveness in managing performance expectations.
Fool
6.5
02-26Fool
Whetstone Capital Fully Exits GitLab Holdings
  • Holding Change: Whetstone Capital Advisors reported in a February 13, 2026 SEC filing that it sold its entire 192,532-share stake in GitLab, with an estimated transaction value of approximately $8.68 million, indicating a significant loss of confidence in the company.
  • Market Performance: As of February 12, 2026, GitLab shares were priced at $29.58, reflecting a 57.6% decline over the past year and trailing the S&P 500 by 70.5 percentage points, highlighting the challenges the company faces in a competitive landscape.
  • Company Overview: GitLab is a leading provider of DevOps lifecycle software, focusing on streamlining and securing software development processes through a unified platform; however, it faces competitive pressure from AI-assisted coding and must adapt to market demands.
  • Investor Focus: As companies reconsider vendor consolidation or adding AI layers, GitLab must standardize its platform and increase enterprise adoption to achieve sustained growth, particularly as demand weakens in some public sector segments and among smaller customers.
NASDAQ.COM
6.5
02-26NASDAQ.COM
Whetstone Capital Fully Exits GitLab Position
  • Share Sale Details: Whetstone Capital Advisors sold all 192,532 shares of GitLab, with an estimated transaction value of $8.68 million, reflecting a significant decline in confidence towards GitLab, resulting in a quarter-end position value drop to zero.
  • Asset Management Impact: This transaction represented 2.7% of Whetstone's 13F reportable AUM, down from 2.4% previously, indicating a notable shift in the fund's investment strategy regarding GitLab.
  • Market Performance Analysis: As of February 12, 2026, GitLab shares were priced at $29.58, down 57.6% over the past year and lagging the S&P 500 by 70.5 percentage points, suggesting low market expectations for its future growth.
  • Strategic Development Challenges: As a leading provider of DevOps lifecycle software, GitLab faces pressures from AI-assisted coding and the need for enterprises to simplify fragmented toolchains, necessitating a conversion of AI integration and customer engagement into sustained enterprise growth while maintaining operational leverage.
Wall Street analysts forecast OPRX stock price to rise
7 Analyst Rating
Wall Street analysts forecast OPRX stock price to rise
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
17.00
Averages
24.33
High
32.00
Current: 0.000
sliders
Low
17.00
Averages
24.33
High
32.00
Stifel
Buy
downgrade
$21 -> $17
AI Analysis
2026-03-06
Reason
Stifel
Price Target
$21 -> $17
AI Analysis
2026-03-06
downgrade
Buy
Reason
Stifel lowered the firm's price target on OptimizeRx to $17 from $21 and keeps a Buy rating on the shares. A challenged environment is reflected in guidance, though this was "largely anticipated," the analyst tells investors in a post-earnings note.
Roth Capital
Buy
downgrade
$32 -> $18
2026-03-06
Reason
Roth Capital
Price Target
$32 -> $18
2026-03-06
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on OptimizeRx to $18 from $32 and keeps a Buy rating on the shares after it's below-consensus revenue guidance. Revenue weakness rapidly emerged as large pharma clients struggle with the Trump administration's "most favored nation" pricing initiative launched in May of 2025, the analyst tells investors in a research note. The firm retains its Buy rating given the already severe valuation pressure on the stock, Roth adds.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OPRX
Unlock Now

Valuation Metrics

The current forward P/E ratio for OptimizeRx Corp (OPRX.O) is 17.59, compared to its 5-year average forward P/E of 57.51. For a more detailed relative valuation and DCF analysis to assess OptimizeRx Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
57.51
Current PE
17.59
Overvalued PE
94.17
Undervalued PE
20.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
52.33
Current EV/EBITDA
13.63
Overvalued EV/EBITDA
99.69
Undervalued EV/EBITDA
4.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
5.68
Current PS
2.03
Overvalued PS
11.11
Undervalued PS
0.24

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

too buy right now for quick gain
Intellectia · 12 candidates
Region: USPrice: $5.00 - $80.00Rsi Category: moderateRelative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEOne Week Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
MCBS logo
MCBS
Metrocity Bankshares Inc
811.81M
ARMN logo
ARMN
Aris Mining Corp
3.51B
NVEC logo
NVEC
NVE Corp
326.46M
HST logo
HST
Host Hotels & Resorts Inc
12.74B
DRD logo
DRD
DRDGOLD Ltd
2.75B
TDC logo
TDC
Teradata Corp
2.66B
what about health tech stocks and robots?
Intellectia · 18 candidates
Market Cap: 50.00M - 50.00BWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ROK logo
ROK
Rockwell Automation Inc
47.26B
SYM logo
SYM
Symbotic Inc
36.98B
TER logo
TER
Teradyne Inc
36.32B
VEEV logo
VEEV
Veeva Systems Inc
36.12B
ZBRA logo
ZBRA
Zebra Technologies Corp
12.31B
DOCS logo
DOCS
Doximity Inc
7.50B

Whales Holding OPRX

R
Rice Hall James & Associates, LLC
Holding
OPRX
+6.92%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is OptimizeRx Corp (OPRX) stock price today?

The current price of OPRX is 6.67 USD — it has increased 1.37

What is OptimizeRx Corp (OPRX)'s business?

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.

What is the price predicton of OPRX Stock?

Wall Street analysts forecast OPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPRX is24.33 USD with a low forecast of 17.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is OptimizeRx Corp (OPRX)'s revenue for the last quarter?

OptimizeRx Corp revenue for the last quarter amounts to 32.24M USD, decreased -0.24

What is OptimizeRx Corp (OPRX)'s earnings per share (EPS) for the last quarter?

OptimizeRx Corp. EPS for the last quarter amounts to 0.26 USD, decreased

How many employees does OptimizeRx Corp (OPRX). have?

OptimizeRx Corp (OPRX) has 106 emplpoyees as of March 12 2026.

What is OptimizeRx Corp (OPRX) market cap?

Today OPRX has the market capitalization of 125.13M USD.